These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 17826370)

  • 21. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease.
    Hao PP; Chen YG; Wang JL; Ji WQ; Xue L; Liu XH; Wang XL; Zhang Y
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):496-500. PubMed ID: 19930422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of revascularization on mortality in patients with nonacute coronary artery disease.
    Jeremias A; Kaul S; Rosengart TK; Gruberg L; Brown DL
    Am J Med; 2009 Feb; 122(2):152-61. PubMed ID: 19185092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty.
    Dens J; Desmet W; Piessens J
    Am Heart J; 2003 Mar; 145(3):404-8. PubMed ID: 12660661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy.
    Kasai T; Miyauchi K; Kurata T; Satoh H; Ohta H; Tanimoto K; Kawamura M; Okazaki S; Yokoyama K; Kojima T; Akimoto Y; Daida H
    Int J Cardiol; 2007 Jan; 114(2):210-7. PubMed ID: 16797744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
    Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V
    Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Lev EI; Kornowski R; Vaknin-Assa H; Ben-Dor I; Brosh D; Teplitsky I; Fuchs S; Battler A; Assali A
    Am J Cardiol; 2009 Jan; 103(2):165-9. PubMed ID: 19121430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
    Leone AM; Rutella S; Giannico MB; Perfetti M; Zaccone V; Brugaletta S; Garramone B; Niccoli G; Porto I; Liuzzo G; Biasucci LM; Bellesi S; Galiuto L; Leone G; Rebuzzi AG; Crea F
    Int J Cardiol; 2008 Nov; 130(3):457-62. PubMed ID: 18667247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level.
    Yamawaki T; Yamada A; Fukumoto Y; Kishi T; Sobashima A; Kuwata K; Nakamura R; Sekiya M; Ando H; Okamatsu S
    Fukuoka Igaku Zasshi; 2007 Jun; 98(6):260-9. PubMed ID: 17665547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
    Veselka J; Zemánek D; Hájek P; Malý M; Adlová R; Martinkovicová L; Tesar D
    Am J Cardiol; 2009 Sep; 104(5):630-3. PubMed ID: 19699335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
    Lemos PA; de Feyter PJ; Serruys PW; Saia F; Arampatzis CA; Disco C; Mercado N; Mainar V; Morís C; van den Bos AA; Berghoefer G
    Int J Cardiol; 2005 Feb; 98(3):479-86. PubMed ID: 15708183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular morbidity associated with nonadherence to statin therapy.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW
    Pharmacotherapy; 2005 Aug; 25(8):1035-43. PubMed ID: 16207093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term treatment with statins in patients with ischemic heart disease after coronary angioplasty].
    Skulec R; Linhart A; Hnátek T; Spundová H; Mrázek V; Bĕlohlávek J; Holm F; Aschermann M
    Vnitr Lek; 2003 Apr; 49(4):285-90. PubMed ID: 12793051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous coronary interventions and statins therapy.
    Nusca A; Melfi R; Di Sciascio G
    Ther Adv Cardiovasc Dis; 2008 Apr; 2(2):101-7. PubMed ID: 19124413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study.
    Hara H; Nakamura M; Yokouchi I; Kimura K; Nemoto N; Ito S; Ono T; Itaya H; Shiba M; Wada M; Iijima R; Yamamoto M; Yamamoto M; Hara H; Takagi T; Asahara T; Mitsuo K; Kobayashi N; Sugi K
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):357-65. PubMed ID: 19638365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
    Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M
    Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
    Nusca A; Melfi R; Patti G; Sciascio GD
    Future Cardiol; 2010 Sep; 6(5):579-89. PubMed ID: 20932108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty.
    Bittl JA; Chew DP; Topol EJ; Kong DF; Califf RM
    J Am Coll Cardiol; 2004 Mar; 43(6):936-42. PubMed ID: 15028347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.